Connect

Member Research and Reports

Member Research and Reports

UAB: NF106 – A Neurofibromatosis Clinical Trials Consortium Phase II Trial Of The MEK Inhibitor Mirdametinib (PD-0325901) In Adolescents And Adults With NF1-Related Plexiform Neurofibromas

Tags: ,